KRAS and non-small cell lung carcinoma: After countless failed attempts [39], sotorasib, the first targeted drug for mutated KRAS, was eventually approved in 2021 by FDA and in 2022 by EMA for the treatment of advanced non-small cell lung cancer (NSCLC) [40].